Vaccines and Blood Products: Two Production Systems with Uneven Evidence
Executive summary
Vaccines and plasma-derived therapies sit within a broad biological-products category, but their supply chains are fundamentally different. Plasma-derived therapies begin with donated human plasma and require fractionation and purification. Vaccines use cell culture or synthesis and do not require plasma as an input. Treating both as one generic biopharmaceutical market obscures where capacity constraints arise.
The strongest quantified constraint found for plasma-derived therapies is the long production cycle: CSL reports 9–12 months from plasma collection through product manufacture. CSL also reported 349 plasma collection centers across China, Europe, and North America in its 2023/24 annual report. For vaccines, Moderna announced a U.S. end-to-end mRNA manufacturing expansion in November 2025, but construction had only begun; the target completion was the first half of 2027, so it is not operating capacity.
The evidence remains incomplete. This review did not find a comprehensive facility and capacity inventory for antibodies, vaccines, and other biological products, nor primary evidence for particular commercial suppliers of mRNA nucleosides and lipids, customer distribution routes, or regional disposal contractors.
Network audit
Two proposed physical-network links were removed because the source review did not substantiate them:
The category is consequently an isolated node in the current physical network. This records the limits of the evidence collected; it does not prove that no such connections exist. Plasma collection and testing, cell-culture media and single-use equipment, adjuvants, mRNA nucleosides and lipids, and packaging remain candidates for future verification.
Production systems
| Stage | Plasma-derived therapies | Vaccines |
|---|---|---|
| Inputs | Donated human plasma | Cell-culture materials, adjuvants, and, for mRNA products, synthesis inputs |
| Manufacturing | Fractionation and purification into therapies such as clotting factors | Cell culture or synthesis, followed by filling |
| Main constraints | Donor availability, collection and testing, long production cycle, consistent quality | Technology, adjuvant supply, facility build-out, lot consistency |
| Approval and supply | FDA biologics licensing and regulated medical supply | FDA licensing and inspections; WHO prequalification can support UN procurement |
| End use | Healthcare providers and patients | Immunization programs and healthcare providers |
CSL reported plasma centers in China, Europe, and North America, and a 9–12 month plasma-derived therapy production cycle. Its Marburg site description covers an integrated chain including fractionation, bulk production, filling, visual inspection, and automated packaging, serving patients in 110 countries. Site-level production capacities were not disclosed.
Thermo Fisher describes providing upstream cell-culture, downstream purification, testing, filtration, separation, and single-use products for biopharmaceutical manufacturing. The cited disclosure does not identify a specific vaccine contract or capacity. GSK reports making its QS-21 adjuvant in-house for vaccines including those for RSV, shingles, malaria, and cervical cancer.
Moderna’s planned Norwood, Massachusetts expansion is intended to enable domestic end-to-end mRNA manufacturing for commercial and clinical supply. It was a construction-stage plan with a first-half 2027 completion target in the cited filing, not an operating facility at the time described.
Approval, quality, and waste
In the United States, biologics licensing applications cover products such as vaccines, blood and blood components, allergens, cellular and gene therapies, and recombinant therapeutic proteins. FDA materials require detailed manufacturing-process and facility information, supporting data on product characteristics and lot consistency, and testing protocols after approval. A facility change or addition can therefore affect supply expansion; output cannot be increased simply by adding generic capacity.
WHO vaccine prequalification reviews product characteristics such as potency, stability, labeling, and transport conditions. Surveillance inspections check continued conformity with WHO GMP and the submitted dossier. This framework supports procurement by UN agencies and member states.
WHO guidance calls for used syringes and needles to be collected in safety boxes and vaccine vials to be collected and disposed of separately from sharps. The reviewed sources did not establish country-level disposal contractors, recovery rates, or handling of unused plasma products and manufacturing residues.